Onxeo Strengthens Beleodaq® Patent Protection in the U.S. until 2027

        Print
| Source: Onxeo SA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News :

Onxeo SA (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ OMX Copenhagen
- ONXEO), an innovative company specialized in the development of drugs for
orphan oncology diseases, today announced that the U.S. Patent Office will grant
a new patent for Beleodaq® (Belinostat U.S. commercial name) on September 16th
2014.

In addition to the existing patent, covering the chemical structure of
Beleodaq®, this new patent also covers the formulation of the product,
strengthening and expanding significantly its industrial property protection
until October 2027 in the U.S.

Beleodaq® also benefits from the commercial exclusivity related to its orphan
status in the US.

Beleodaq® has obtained Marketing Authorization from the Food and Drug
Administration (FDA) for the treatment of patients with relapsed or refractory
peripheral T-cell lymphoma (R/R PTCL) in early July 2014. PTCL accounts for
around 10 to 15% of non-Hodgkin's lymphoma and its global incidence is estimated
at 12,000 cases each year.

“This new patent significantly increases the value of our product”, commented
Judith Greciet, CEO of Onxeo. “Indeed, it extends the period of market
exclusivity, and it will foster the initiation of other promising indications’
development with our U.S. partner Spectrum Pharmaceuticals”.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.
Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Contacts
Onxeo
Judith Greciet, CEO, +33 1 45 58 76 00
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO, +33 1 45 58 76 00
n.fellmann@onxeo.com
or
Caroline Carmagnol / Sophie Colin – Alize RP
+33 6 64 18 99 59 / +33 6 31 13 76 20
caroline@alizerp.com / scolin@alizerp.com
or
Michael Steen-Knudsen , +45 25 17 18 15
Impact Communications